Good find. The article is assumes there are 4000 patient per year. not the more modest 3000 npsp is assuming. NPSP has a habit of under promising and over delivering. Notoriety about the co will eventually result in prices which are much higher that the present. The ten million shares short will in the next few months create a potential massive stampede to cover. I assume MOST shorts are now UNDER WATER. We could see brokers calling their short clients asking them to cover their positions.
I agree , NPS does under promise and then over delivers. I like that. I think it's true as well, that we seem to hear more and more references about "orphan drugs". I remember when I got into the market about 1year ago , I had to look it up in Investopedia. I thought about it and kind of do remember when there wasn't anybody working on these rare diseases until the FDA created "orphan drug " status. As it turns out 3 out of the 4biotech's I own have orphan drug status. I didn't even plan that I was just attracted to them.
And I'll say it again, I feel very safe with my investment at NPSP.